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ORIGINAL ARTICLE
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analysis of the multi-biomarker disease activity score and conventional
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ABSTRACT
Objective: To compare the multi-biomarker disease activity (MBDA) score with the DAS28-CRP and
CRP for predicting risk of radiographic progression in patients with rheumatoid arthritis.
Methods: Published studies of the MBDA score and radiographic progression with 100 patients per
cohort were evaluated. Rates of radiographic progression over 1 year were determined across the low/-
moderate/high categories for MBDA score (low/moderate/high: <30, 30–44, >44), DAS28-CRP (low/
moderate/high: 2.67, >2.67–4.09, >4.09) and CRP (low/moderate/high: 10, >10–30, >30mg/L),
with positive and negative predictive value (PPV, NPV) and relative risk (RR) determined for high vs.
not-high (i.e. low and moderate combined) categories. Patient-level data from studies having all three
measures was pooled to: (1) determine a combined RR for radiographic progression in the high vs.
not-high categories for each measure; and (2) compare the predictive ability of MBDA score vs.
DAS28-CRP by comparing the rates of radiographic progression observed in subgroups created by
cross-classifying the high and not-high categories of each measure.
Results: Five cohorts were identified for inclusion (total N¼929). In each, radiographic progression was
more frequent with increasing MBDA scores. Among the three cohorts with requisite data, PPVs were
generally similar using categories of MBDA score, DAS28-CRP or CRP but NPVs were greater for MBDA
score (93–97%) than DAS28-CRP or CRP (77–87%). RRs for radiographic progression were greater when
based on categories of MBDA score than DAS28-CRP or CRP and the combined RR was greater for
MBDA score (4.6, p< .0001) than DAS28-CRP (1.7, p¼ .02) or CRP (1.7, p¼ .002). For patients cross-clas-
sified by MBDA score and DAS28-CRP, high vs. not-high MBDA score significantly predicted radio-
graphic progression independently of DAS28-CRP.
Conclusions: High and not-high MBDA scores were associated with increased and low risk, respect-
ively, for radiographic progression over one year. MBDA score was a better predictor of radiographic
progression than DAS28-CRP or CRP.
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Introduction
The primary goals of treatment for rheumatoid arthritis (RA)
are to control inflammation, prevent joint damage and
minimize disability. Guidelines recommend that RA disease
activity be assessed regularly, with treatment adjusted as
needed to achieve remission or the lowest possible level of
disease activity1,2. The conventional measures for assessing
RA disease activity involve various combinations of joint
counts and physician and patient global assessment, which
are partially subjective and variable between physicians, and
blood testing for C-reactive protein (CRP) or erythrocyte
sedimentation rate, which can be normal in patients with
active disease3.
The multi-biomarker disease activity (MBDA) blood test
measures 12 protein biomarkers in the serum of RA patients
and uses a validated algorithm to produce a score on a scale
of 1–100 that objectively represents the current level of RA
disease activity4,5. The MBDA score correlates with the
Disease Activity Score with 28 joints using CRP (DAS28-CRP)
and other clinical measures of disease activity, and change in
MBDA score correlates with change in DAS28-CRP and other
measures4,6,7. The MBDA score was validated in seropositive
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and seronegative patients with RA and in patients receiving
conventional synthetic disease modifying anti-rheumatic
drugs (DMARDs) and TNF inhibitors (TNFi)4. Spearman’s rank
correlations for MBDA score vs. DAS28-CRP, Simplified
Disease Activity Index (SDAI) and Clinical Disease Activity
Index (CDAI) were 0.66, 0.67 and 0.56, respectively (all
p< .0001)7. In seropositive patients, Pearson’s correlation
coefficient for MBDA score vs. Routine Assessment of Patient
Index Data was 0.47 (p< .001)4.
That the MBDA score detects not only clinically meaning-
ful disease activity but also severity has been supported by
studies demonstrating its association with radiographic pro-
gression, as assessed with the van der Heijde modified Sharp
score (SHS)8. In several studies, rate of radiographic progres-
sion over one year was greatest among patients with base-
line MBDA scores in the high category (>44) and lowest
among patients with baseline MBDA scores in the low cat-
egory (<30)9–14. Patients with moderate MBDA scores
(30–44) tended to have progression rates almost as low as
those with low MBDA scores. Cross-classification analyses
showed that the MBDA score predicted risk for radiographic
progression even when it was discordant with DAS28-CRP or
CRP, such as when the MBDA score was high and conven-
tional measures indicated low disease activity14. Multivariate
analyses showed that the MBDA score was the strongest
independent predictor of radiographic progression, com-
pared with DAS28-CRP, CRP and other risk factors for radio-
graphic progression9,10,13,14.
The ability of MBDA score to predict radiographic progres-
sion suggests that it has potential to help physicians assess risk
for radiographic progression in their patients. It also supports
the clinical validation of the MBDA score with radiographic evi-
dence that the MBDA score detects disease activity that is not
always captured by clinical measures but has the ability to
induce joint damage. Studies that examined the relationship
between MBDA score and radiographic progression are diverse
and have never been evaluated collectively. The purpose of the
present study was to systematically analyze prior studies to
evaluate the ability of the MBDA score to predict radiographic
progression and, in combined analyses, to compare this ability
with those of DAS28-CRP and CRP.
Methods
Review of the literature
Studies that analyzed the association between MBDA score
and risk for radiographic progression were identified for the
present study by a review of the literature, based on a
PubMed search of the terms “multi-biomarker rheumatoid”
and “multibiomarker rheumatoid”, last updated 8 October
2018. All studies that analyzed the association between
MBDA score and risk for radiographic progression were ini-
tially selected. Studies of same cohorts that did not add new
data to the analyses of radiographic progression specified
here were excluded, as were studies in which the primary
purpose was to evaluate treatment withdrawal and studies
that analyzed MBDA score as a predictor of radiographic pro-
gression only for groups of <100 patients.
Clinical measures
DAS28-CRP was selected for analysis because it was available
from more of the selected studies than other clinical composite
disease activity measures (e.g. CDAI or SDAI). The DAS28-CRP
categories employed here, remission/low 2.67 (termed “low”,
hereafter), moderate >2.67–4.09 and high >4.09, have been
established previously15. DAS28-CRP categorical data were
obtained from publications that used these categories10,12 or
new analyses of patient-level data, if available9. If neither
option was possible, the categories used previously for
DAS28-CRP in that study, such as the conventional DAS28-ESR
categories of remission/low <3.2, moderate 3.2–5.1 and high
>5.1, were used here16,17. The CRP categories employed here
were low 10mg/L, moderate >10–30mg/L and high
>30mg/L, to be consistent with prior publications on the
MBDA score10,14 and with the ACR/EULAR definition of Boolean
remission (CRP < 10mg/L)18. CRP data was obtained from pub-
lished results10 or from patient-level data9,12, if available.
Radiographic measures
Studies to be included here were required to have obtained
radiographs of hands and feet at baseline and Year 1, to
have scored them with the total Sharp score (TSS) or SHS
and to have used the data to evaluate the association
between MBDA score and risk for radiographic progression.
For the present analyses, patients were characterized as pro-
gressors or non-progressors according to change (D) in TSS
or SHS from baseline to Year 1, based on thresholds for
radiographic progression published previously for each
respective study.
Multi-Biomarker Disease Activity score measurement
For each cohort included here, MBDA testing had been per-
formed previously on serum samples that had been shipped
frozen to the laboratories of Crescendo Bioscience Inc., in
South San Francisco, CA, USA, for testing9,10,12,16,17. Serum
concentrations were determined by electrochemilumines-
cence-based multiplexed sandwich immunoassays (Meso
Scale Discovery, Rockville, MD, USA) for the following 12 bio-
markers: vascular cell adhesion molecule 1, epidermal growth
factor, vascular endothelial growth factor, interleukin 6, TNF
receptor type I, matrix metalloproteinase (MMP) 1, MMP-3,
bone glycoprotein 39 (YKL-40), leptin, resistin, serum amyloid
A and CRP5. The MBDA score was calculated on a scale of
1–100 using a previously validated algorithm4,5. MBDA dis-
ease activity categories were low <30, moderate 30–44 and
high >44, as established previously4. Samples from all
cohorts were tested with the same types of reagents and
instrument, and MBDA scores were determined with the
same algorithm as are used for the Vectra test, which has
been commercially available in the United States since 2010.
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Statistical analyses
Data availability
The methodology of this study was adapted to be aligned
with the availability of patient-level data from the selected
studies, after they were identified, and to fill gaps in pub-
lished analyses, where needed. Among the studies identified
for the present analyses (Leiden University Early Arthritis
Clinic (Leiden)12,14, the Optimized Treatment Algorithm for
Patients with Early Rheumatoid Arthritis trial (OPERA)9, the
Swedish Farmacotherapy trial (SWEFOT)10 and the Abatacept
versus Adalimumab Comparison in Biologic-Naive RA
Subjects with Background Methotrexate trial (AMPLE)16,17,
patient-level data were available for cohorts from Leiden,
OPERA and SWEFOT. Patient-level data were not available
from the AMPLE study. Analyses of AMPLE were thus
restricted to group-level data that could be analyzed based
on published results.
Distribution of disease activity
The distributions of patients in the low, moderate and high
disease activity categories of MBDA score, DAS28-CRP and
CRP, as defined above, were determined from published
data, preferentially, or patient-level data, at the same time-
point used in previous studies of the relationship between
disease activity and radiographic progression (i.e. baseline for
Leiden, OPERA and SWEFOT, and Year 1 for AMPLE).
Association between radiographic progression and dis-
ease activity
The association between radiographic progression from base-
line to Year 1 and disease activity was evaluated by deter-
mining the percentages of patients with radiographic
progression within low, moderate and high disease activity
categories for MBDA score, DAS28-CRP and CRP. Based on
data availability, these analyses used published data, prefer-
entially, or patient-level data. Radiographic progression in
the Leiden registry cohort was analyzed for each disease
activity measure with patient-level data and included only
baseline visits (N¼ 163), rather than all 271 visits as in previ-
ous reports12,14. Radiographic progression in OPERA had not
been previously reported by CRP category9, which was ana-
lyzed here using patient-level data. The other analyses of
radiographic progression by disease activity category for
OPERA and all those for SWEFOT used published results, with
patient-level data used for confirmation9,10. Radiographic
progression in AMPLE, for which patient-level data were
unavailable, had not been previously reported by category of
DAS28-CRP or CRP16,17. Thus, it was analyzed here only by
category of MBDA score. Disease activity was categorized at
the same timepoint used in previously published analyses of
the MBDA score as a predictor of risk for radiographic pro-
gression (baseline for Leiden, OPERA and SWEFOT, Year 1 for
AMPLE). Progressors were defined here using the previously
published DSHS threshold for each cohort. The
Cochran–Armitage trend test was used to determine whether
the rates of radiographic progression exhibited a trend, from
the low to moderate to high disease activity categories, with
p values <.05 considered significant.
Sensitivity, specificity, positive predictive value, negative
predictive value and relative risk
Data used to evaluate the association between radiographic
progression and disease activity category were also used to
determine the corresponding values for sensitivity, specificity,
positive predictive value (PPV), negative predictive value
(NPV) and relative risk (RR), with disease activity categorized
as high or not-high (i.e. low and moderate categories
together) and radiographic progression defined for each
study using the previously published threshold for DSHS. The
moderate and low groups were analyzed together because
radiographic progression rates in the moderate groups were
more similar to those in the low group than the high
group9,10,12,14, and because prior analyses demonstrated an
upward inflection in the progression rate as MBDA scores
entered the high category14. PPV for MBDA score, DAS28-
CRP or CRP was calculated as the percentage of patients in
the high disease activity category who had radiographic pro-
gression from baseline to Year 1. NPV was calculated as the
percentage of patients in the combined low and moderate
(i.e. not-high) disease activity categories who did not have
radiographic progression at Year 1. Relative risk (RR) of radio-
graphic progression, with 95% confidence interval (CI), was
calculated for patients with high vs. not-high MBDA score
(>44 vs. 44), DAS28-CRP (>4.09 vs. 4.09) or CRP (>30 vs.
30mg/L), respectively, as PPV/(100 - NPV). Statistical signifi-
cance for the RR of each disease activity measure was deter-
mined by Fisher’s exact test; p values <.05 were considered
significant.
Combined analysis of relative risk for radiographic
progression
Data on the numbers of progressors by category of disease
activity for individual cohorts were pooled to determine the
overall RR for radiographic progression (with 95% CI) for the
high vs. not-high categories of baseline MBDA score, DAS28-
CRP and CRP. Data were pooled only for cohorts for which
RR could be determined for all three measures (i.e. Leiden,
OPERA and SWEFOT). The methodology was the same as for
determining RR in the individual cohorts, described above.
Comparison of Multi-Biomarker Disease Activity score and
DAS28-CRP as predictors of radiographic progression by
cross-classification
Patient-level data on progressor status, and category of
MBDA score and DAS28-CRP were pooled to cross-classify
patients into four subgroups, based on high or not-high
baseline MBDA score and DAS28-CRP. The percentage of
patients with radiographic progression from baseline to one
year was determined for each subgroup, with radiographic
progression defined using the published cohort-specific
thresholds. Only cohorts for which RR could be determined
for MBDA score and DAS28-CRP were included (i.e. Leiden,
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OPERA and SWEFOT); p values for comparisons between sub-
groups were determined by Fisher’s exact test.
Results
Patient cohorts
A review of the literature identified four studies and, from
them, five cohorts of at least 100 patients each (total
N¼ 929), that were suitable for inclusion in this analysis
(Figure 1). These cohorts were from the Leiden University
Early Arthritis Clinic (N¼ 163)12,14, the OPERA trial (N¼ 164)9,
the SWEFOT trial (N¼ 235)10 and the AMPLE trial (two
cohorts: abatacept arm, N¼ 181 and adalimumab
arm, N¼ 186)16,17.
The Leiden cohort comprised a representative, cross-sec-
tional sampling of patients from that registry who were
receiving non-biologic DMARDs, of whom <5% were receiv-
ing a TNFi by one year from the baseline MBDA sample12,14.
The OPERA, SWEFOT and AMPLE cohorts were from the first
year of randomized trials that initiated new treatments at
baseline, and were selected on the basis of sample
availability for MBDA testing9,10,17; OPERA and SWEFOT each
employed tight-control strategies for patients with recent
onset RA; OPERA randomized patients to two arms, where
methotrexate was given either as monotherapy or in com-
bination with adalimumab, with each arm following a tight-
control strategy that included intra-articular corticosteroid
injections; SWEFOT treated all patients with methotrexate
monotherapy from baseline and, at three months, random-
ized patients with DAS28> 3.2 to add either hydroxychloro-
quine and sulfasalazine or infliximab, with all other patients
(DAS28 3.2) continuing methotrexate monotherapy. AMPLE
initiated continuous treatment with abatacept or adalimu-
mab at baseline for patients with established RA and inad-
equate response to methotrexate19. The present analyses
used the same cohorts as those described in previous reports
of the MBDA score as a predictor of radiographic progres-
sion9,10,12,14,16,17. For OPERA and SWEFOT, respectively, all
patients were analyzed as a single group. For AMPLE, the
abatacept and adalimumab arms were analyzed separately.
The characteristics of these cohorts have been previously
described in detail and are summarized in Table 1.
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Distributions of disease activity
For each cohort, the distributions of patients across disease
activity categories were assessed at the timepoint used to
analyze the relationship between disease activity and radio-
graphic progression. At baseline, MBDA score and DAS28-
CRP were high for most patients in the OPERA and SWEFOT
cohorts, whereas MBDA score and DAS28-CRP were low or
moderate for the majority of patients from Leiden at baseline
and AMPLE at Year 1 (Supplemental Figure 1). Year 1 was
the only timepoint at which categorical MBDA data were
available in analyses of radiographic progression from base-
line to Year 1 for AMPLE16,17. Patients tended to be in higher
disease activity categories by the MBDA score compared
with CRP in the Leiden, OPERA and SWEFOT cohorts and
compared with DAS28-CRP in the Leiden and AMPLE cohorts
(Supplemental Figure 1). Data were not available from
AMPLE for categorizing patients by CRP category.
Association between radiographic progression and
disease activity
When patients were grouped by MBDA category, the per-
centage of patients with radiographic progression was
greatest among patients with high MBDA scores and least
among those with low MBDA scores (Figure 2). This trend
was statistically significant in all five cohorts. The magni-
tude of trend, from low to high MBDA category, was
similar for the five cohorts, even though the overall rates
of progression were greater for the Leiden, OPERA and
SWEFOT cohorts (17–26%), in which not all patients
received a biologic agent, than the AMPLE cohorts (10%,
11%), where all patients were randomized to receive aba-
tacept or adalimumab for the entire year of radiographic
assessment (Table 2).
Trends were also observed in the rates of radiographic
progression across categories of DAS28-CRP and CRP for the
cohorts from Leiden, OPERA and SWEFOT (studies for which
those data were available), but they were not statistically sig-
nificant or were less significant than across MBDA categories
(Figure 2). Radiographic progression was observed in greater
percentages of patients in the low or moderate disease activ-
ity categories of DAS28-CRP or CRP (12–26%) than in the low
(0–4%) or moderate (3–10%) categories of MBDA score
(Figure 2). For each measure, rates of progression in the
moderate categories were numerically closer to those
observed in the low categories than the high categories (not-
ing that the progression rate in the low CRP category of
OPERA is 20.3%).
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gression thresholds were as previously defined for each study (in footnotes and Table 1); p values are by Cochran–Armitage trend test.
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Sensitivity, specificity, positive predictive value,
negative predictive value and relative risk for
radiographic progression
In the Leiden, OPERA and SWEFOT cohorts, sensitivity for
radiographic progression, using high and not-high disease
activity categories, was numerically greatest when based on
MBDA categories (Table 2); specificity was greatest with CRP
categories. Results in the AMPLE cohorts, for which only
MBDA results were available, were most similar to those
from Leiden.
PPVs for radiographic progression, based on the high
MBDA category, were 18–31% among the five cohorts
(Figure 2, Table 2). PPVs based on the high DAS28-CRP or
CRP categories were similar to the MBDA-score-based PPVs
in the Leiden, OPERA and SWEFOT cohorts, although the
Leiden high-CRP category, with only 11 patients, had a
PPV of 55%. NPVs for radiographic progression based on
MBDA categories were 93–97% among the five cohorts
(Table 2). For the Leiden, OPERA and SWEFOT cohorts,
these NPVs were all numerically greater than those
obtained with DAS28-CRP or CRP categories (77–87%). The
relative risks for radiographic progression, based on high
vs. not-high categories in the Leiden, OPERA and SWEFOT
cohorts, were greater when based on MBDA categories
(4.3–9.6) than DAS28-CRP (1.4–2.1) or CRP (1.4–3.6) catego-
ries (Table 2). In the OPERA and SWEFOT cohorts,
the RRs were statistically significant only with
MBDA categories.
Combined analysis of relative risk for radiographic
progression
Data from cohorts in which radiographic progression could
be assessed by category of MBDA score, DAS28-CRP and CRP
– the Leiden, OPERA and SWEFOT cohorts – were pooled to
determine the overall relative risks for progression for each
measure. The combined RR of radiographic progression,
comparing individuals with a high MBDA score (>44) to all
others (44), was 4.6 (p¼ .0001, 95% CI: 2.4–8.9), which was
approximately three times as large as the corresponding RRs
based on categories of DAS28-CRP (1.7, p¼ .02, 95% CI:
1.1–2.6) or CRP (1.7, p¼ .002, 95% CI: 1.2–2.4) (Figure 3).
Comparison of Multi-Biomarker Disease Activity score
and DAS28-CRP by cross-classification
To further compare the abilities of MBDA score and DAS28-
CRP to predict radiographic progression in the combined
Leiden, OPERA and SWEFOT cohorts, patients were cross-clas-
sified into four subgroups based on high and not-high cate-
gories of MBDA score and DAS28-CRP. The percentages of
patients with radiographic progression were highest when
the baseline MBDA score was high and lowest when it was
not high (Figure 4). This result was observed both when
MBDA score and DAS28-CRP were concordant (p¼ .0001),
which occurred in 76% of patients, and when they were dis-
cordant (i.e. one high, the other not high; p¼ .002), which
occurred in 24% of patients. In particular, among the 147
Table 2. Prediction of radiographic progression by the MBDA score, DAS28-CRP or CRP by grouping patients in the high and not-high (i.e. low/moderate) cate-
gories for each measure.
Leiden OPERA SWEFOT AMPLE
Abatacept Adalimumab
RP threshold (DSHS) >5 2 >5 >SDC16,17,19 >SDC16,17,19
Overall rate of radiographic progression 17% 26% 18% 10% 11%
MBDA score (high: >44)
Patients, N 163 164 235 181 186
Sensitivity 75% 98% 98% 79% 57%
Specificity 66% 25% 17% 59% 77%
PPV 31% 31% 21% 18% 24%
NPV 93% 97% 97% 96% 93%
Relative risk (95% CI) 4.3 (1.9, 9.5) 9.6 (1.4, 66.8) 7.1 (1.0, 49.9) 4.5 (1.6, 13.1) 3.6 (1.6, 8.1)
p value <.0001 .001 .008 .003 .002
DAS28-CRP (high: >4.09)
Patients, N 156 164 235 – –
Sensitivity 46% 95% 93% – –
Specificity 74% 11% 10% – –
PPV 28% 27% 19% – –
NPV 86% 87% 86% – –
Relative risk (95% CI) 2.1 (1.1, 4.0) 2.0 (0.5, 7.5) 1.4 (0.5, 4.1) – –
p value .04 .36 .77 – –
CRP (high: >30mg/L)
Total N 156 164 235 – –
Sensitivity 21% 38% 51% – –
Specificity 96% 72% 65% – –
PPV 55% 32% 25% – –
NPV 85% 77% 86% – –
Relative risk (95% CI) 3.6 (1.9, 7.0) 1.4 (0.8, 2.4) 1.7 (1.0, 2.9) – –
p value .005 .25 .06 – –
Disease activity categorization was at baseline for Leiden, OPERA and SWEFOT and at Year 1 for AMPLE; p values for RR are by Fisher’s exact test. Radiographic
data by category of DAS28-CRP or CRP was not available for AMPLE.
Abbreviations. NPV, Negative predictive value (% with no radiographic progression in the not-high category); PPV, Positive predictive value (% with radiographic
progression in the high category); RR, Relative risk (PPV/[1 - NPV]); SDC, Smallest detectable change; SHS, modified Sharp–van der Heijde score.
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patients whose DAS28-CRP was not high, 62 (42%) had a
high MBDA score; among them, the percentage of patients
with radiographic progression (21%) was significantly greater
than when DAS28-CRP and MBDA score were both not high
(8.2%, p¼ .03) (Figure 4). By contrast, the DAS28-CRP did not
significantly discriminate risk of radiographic progression
among patients grouped by MBDA category (p¼ .43 for
DAS28-CRP when MBDA scores were high; p¼ .19 for DAS28-
CRP when MBDA scores were not high).
Discussion
These analyses of five cohorts of RA patients with different
disease activity and treatment histories show that a high
MBDA score was consistently a significant predictor of
increased risk for radiographic progression, and a low or
moderate MBDA score was consistently a strong predictor of
low risk for radiographic progression. When RRs were deter-
mined for multiple cohorts combined, the relative risk of
radiographic progression was approximately three times as
large when based on categories of MBDA score versus cate-
gories of DAS28-CRP or CRP. Based on these results, the
MBDA score had a stronger association with joint-damaging
inflammation over the following year than did the conven-
tional clinical (DAS28-CRP) or biochemical (CRP) measures of
RA disease activity that were assessed here.
The most notable finding in the analyses of individual
studies was that rates of radiographic progression in the low
and moderate categories of MBDA score approached zero
and, thus, the corresponding NPVs approached 100%
(93–97% in the five cohorts). By contrast, radiographic pro-
gression rates were higher (12–25%) and NPVs were lower
(77–87%) for low or moderate categories based on DAS28-
CRP or CRP. This difference is clinically relevant because it
implies that a not-high MBDA score provides greater confi-
dence that a patient will not progress than do not-high val-
ues of DAS28-CRP or CRP. This finding may have value for
patients who have not attained a target of clinical low dis-
ease activity but have nevertheless achieved a low or moder-
ate MBDA score.
We found that for all three measures, MBDA score, DAS28-
CRP and CRP, the high disease activity category was associ-
ated with the highest rate of radiographic progression, with
PPVs of 18–32% (in the groups with more than 11 patients).
The range of PPVs observed here is consistent with the rela-
tively low overall rates of radiographic progression in these
studies and with evidence that radiographic progression can
be disconnected from clinical state20. High MBDA scores may
be informative when conventional measures detect low dis-
ease activity. Previous analyses of the Leiden and SWEFOT
cohorts found that high MBDA scores identified patients at
increased risk for progression among those who were in
DAS28-CRP remission12, had low CRP (<1.0mg/dL)10,14 or
had no swollen joints14. Those findings, reinforced by the
present analyses, suggest that the MBDA score detects
subclinical disease. They are also consistent with evidence
that, in RA patients who are in sustained clinical remission,
MRI frequently detects synovitis and osteitis, which are
associated with structural progression21,22, and with a
study of >9000 patients with clinically active RA, among
whom the majority had a CRP concentration in the nor-
mal range3.
Combined analysis of data from three studies found the
MBDA score was approximately three times as effective as
DAS28-CRP or CRP for predicting radiographic progression
(Figure 3). Previously, cross-classification analyses and multi-
variate analyses showed the MBDA score was an independ-
ent predictor of risk for radiographic progression, compared
with conventional risk factors9,10,13,14. In our cross-classifica-
tion analysis of three cohorts combined, these findings were
confirmed because radiographic progression was most fre-
quent when MBDA score was high, both when DAS28-CRP
was high and when it was not high (Figure 4). These radio-
graphic findings imply that the MBDA score has potential to
detect subclinical inflammation that is not apparent on joint
examination and, conversely, to identify patients with non-
inflammatory pain, as when the DAS28-CRP is elevated and
the MBDA score is not. Matrix analyses have shown comple-
mentarity among conventional predictors of risk for radio-
graphic progression23–27. Similarly, the MBDA score is
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complementary to DAS28-CRP and CRP10,12–14. For patients
with discordant MBDA score and DAS28-CRP, physicians
need to evaluate all available information to treat symptoms
optimally and to limit radiographic progression.
Two of the cohorts in the combined analyses, OPERA and
SWEFOT, were skewed toward patients with high disease
activity because those studies enrolled only patients with clin-
ically active, untreated disease (Supplemental Figure 1)9,10. By
contrast, typical clinical practice populations may have larger
proportions of patients with not-high (i.e. low or moderate)
DAS28-CRP and, as a result, proportionally more discordance
between DAS28-CRP and MBDA score, either as not-high
DAS28-CRP/high MBDA score or high DAS28-CRP/not-high
MBDA score. This effect was observed in the cohort from the
Leiden registry, where these types of discordance were
observed in 35% of patient visits14, compared with 24% of
patients in the OPERA, SWEFOT and Leiden cohorts combined
(Figure 4) and with 19% of patients from SWEFOT alone10.
The two AMPLE cohorts were derived from a clinical trial
that enrolled previously treated patients with clinically active
disease (DAS28-CRP >3.2)19. These cohorts were the only
ones where every patient was randomized to receive a bio-
logic treatment for the entire time analyzed, making their
results complementary to those of the other cohorts. A prior
report16,17 analyzed the relationship between radiographic
progression and MBDA scores in AMPLE differently from the
present study, where we re-analyzed published data from
AMPLE16,17 in terms of the percentage of progressors within
each disease activity category28. The associations we found
between MBDA score and radiographic progression in
AMPLE resembled those obtained in the Leiden, OPERA and
SWEFOT cohorts, even though in AMPLE the overall rates of
progression were lower than in the other three cohorts and
the risk for radiographic progression in AMPLE was analyzed
using MBDA scores from the end of Year 1, rather than base-
line – an approach that, although not ideal, has been used
previously29 and was predicated here on the unavailability of
patient-level data from AMPLE. The findings obtained here
for AMPLE are also consistent with studies which found that,
while treatment with a biologic plus MTX reduced the rate
of radiographic progression at all levels of clinical response,
the rate of progression was greatest among patients with
poor clinical responses29,30.
A limitation of this study is that it analyzed only five
cohorts, as it was restricted to published studies with data
available for at least 100 patients per cohort. Analyses of the
relationship between radiographic progression and MBDA
score have also been reported for cohorts from four other
studies of newly initiated treatments: for patients with recent
onset RA from CAMERA6 and BeSt13, which are studies of
tight-control treatment strategies, and for two studies of
patients with long-standing RA treated with TNF inhibi-
tors31,32. These four studies were not included here because
of small sample size. For patients from the CAMERA study, a
multivariate logistic regression analysis found that baseline
MBDA score was borderline significant (p¼ .09) as an inde-
pendent predictor of radiographic progression, whereas
DAS28 was not a significant predictor (p¼ .60)6. Analyses of
patients from BeSt found a significant association between
baseline MBDA score and radiographic progression, with
MBDA score predicting progression independently of DAS
and other predictors in a multivariate analysis13. In a study of
patients receiving adalimumab, etanercept or infliximab,
baseline MBDA score was significantly associated with radio-
graphic progression and, among patients with low baseline
DAS28, radiographic progression was greater among patients
with moderate or high baseline MBDA scores than those
with low MBDA scores31. In the HURRAH study, after six
months of treatment with adalimumab plus MTX, MBDA
score, MRI and ultrasound were generally concordant in
showing signs of inflammation in patients with DAS28-CRP
< 2.6, and MBDA scores were elevated in all patients with
damage progression32. The results of these studies are con-
sistent with those analyzed here.
We recognize that the studies we analyzed differed in the
thresholds for DSHS they used to define radiographic pro-
gression over one year (Tables 1 and 2). OPERA and AMPLE
used the SDC, which is unique for each study, and Leiden
and SWEFOT used 5 Sharp units per year, typically consid-
ered a definition of rapid radiographic progression23. For
each study, the patient population and treatment regimen
had a unique relationship to risk for radiographic progression
and radiographs were read independently, with readers
aligned within but not between studies. Thus, to preserve
those relationships, we classified patients in a binary way as
progressors or non-progressors in each study using their
respective thresholds for radiographic progression.
Conclusions
In conclusion, we performed a review of the literature to
evaluate prior analyses of the MBDA score as a predictor of
risk for radiographic progression. Five cohorts that included
patients receiving diverse non-biologic and biologic treat-
ments in early or established RA fulfilled inclusion criteria. In
all studies, a high MBDA score was associated with greater
risk for radiographic progression over one year than low or
moderate MBDA scores, and a low MBDA score was associ-
ated with very low absolute risk for radiographic progression.
MBDA score had a greater NPV for radiographic progression
than DAS28-CRP or CRP, suggesting that it was the best per-
forming instrument of the three for identifying which
patients are at little or no risk for radiographic progression. A
combined analysis comparing patients with high vs. not-high
disease activity demonstrated that MBDA score was approxi-
mately three times better for predicting radiographic pro-
gression than DAS28-CRP or CRP. These findings suggest
that the MBDA score is a more accurate measure than
DAS28-CRP or CRP for assessing pathologically meaningful
disease activity that damages joints.
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